CD33 and non-Hodgkin lymphoma: To improve efficacy of the anti-CD20-MAb (rituximab) and of the anti-CD33-MAb (HuM195, lintuzumab) used in treatment of non-Hodgkin's lymphoma (NHL) and acute myeloid leukemia (AML), respectively, coupling of radionuclides has turned out beneficial [21-24].